ChemoCentryx ContactSite Map
News & Events

Overview

Corporate Governance

Annual Reports

SEC Filings


Stock Information

Press Releases

Events & Presentations

contact Info

FAQs

Shareholder Tools

ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.

Stock Chart
Stock price graph
     
Stock Quote
NASDAQ: CCXI
Price:
8.22
Change:
- 0.60
Day High:
9.10
Day Low:
8.16
Volume:
403,800
4:00 PM ET on Jan 30, 2015
Delayed at least 20 minutes.
Provided by eSignal.

View all »   RSSRecent News

Jan 6, 2015
ChemoCentryx to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2014
ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140

Dec 11, 2014
ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II Results in Patients With Diabetic Nephropathy With CCX140, an Orally Administered CCR2 Inhibitor

^ Return to Top